A Study of Tirzepatide Administered by Two Different Devices in Healthy Participants
Status:
Completed
Trial end date:
2019-12-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the amount of tirzepatide that gets into the blood
stream and how long it takes the body to get rid of it, when given as a solution formulation
via an autoinjector versus a conventional prefilled syringe. The tolerability of tirzepatide
will also be evaluated and information about any adverse effects experienced will be
collected.
Screening is required within 28 days prior to the start of the study. For each participant,
the total duration of the clinical trial will be about 14 weeks, including screening.